[REVISION HISTORY]

Atrial fibrillation stroke prevention and cognitive research

Updated 3 times since CLSTR started tracking revisions of this situation.

What changed

2026-09-27 17:32 UTC → 2026-10-03 11:35 UTC · added ~~removed~~

Clinical research has increasingly supported the use of oral anticoagulants (OAC) for stroke prevention in patients with atrial fibrillation (AF) at intermediate risk. Data from the SINGLE-AF trial, published in The New England Journal of Medicine, indicates that direct oral anticoagulants (DOAC) can reduce serious clinical events. ~~In a South Korean~~ Led by Professor Boyoung Joung at Yonsei University, the study of followed 1,803 participants ~~over 24 months,~~ across 18 medical centers in South Korea for two years. While high-risk patients are routinely prescribed blood thinners and low-risk patients often are not, the benefits for intermediate-risk patients have previously lacked randomized trial data. The findings, presented at ESC Congress 2026, showed that the primary outcome—a combination of stroke, systemic embolism, major hemorrhage, or cardiovascular death—occurred in 0.5% of the treated group compared to 1.5% in the untreated group, representing a relative risk reduction of approximately 69%. Stroke frequency was also lower in the treated group, with three cases compared to ten in the control group. A meta-analysis in JAMA Cardiology suggested that transcatheter left atrial appendage closure (LAAC) should not be a routine first-line alternative to OAC, as it was associated with a 34% higher risk of ischemic stroke compared to anticoagulation. Recent research from the Karolinska Institutet in Sweden, published in the European Heart Journal, suggests potential cognitive benefits for patients with both Alzheimer’s disease and atrial fibrillation. Analyzing data from 7,308 individuals via Sweden’s national dementia registry, the study found that patients using newer non-vitamin K oral anticoagulants (NOACs) experienced a slower decline in Mini-Mental State Examination (MMSE) scores—approximately 0.21 to 0.23 points per year—compared to those using warfarin or no anticoagulants. Professor Maria Eriksdotter noted that the effect might be due to ‘improved blood flow and reduced small-scale brain damage’ and could become more significant over longer periods.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.